Tempus' $1.5B Acquisition of Personalis Highlights Expanding Role of MRD in Precision Oncology
Market Chameleon (Mon, 20-Jul 9:15 AM)
Personalis Secures UKCA Mark for NeXT Personal Dx, Paving Way for Faster Biopharma Trials and MRD Diagnostics in Great Britain
Market Chameleon (Tue, 14-Jul 8:59 AM)
Personalis Reaches Major EU Milestone with CE-IVD Blood Collection Kits for Precision Oncology Partners
Market Chameleon (Tue, 9-Jun 7:11 AM)
Personalis Wins Key Medicare Coverage for Breast Cancer Test—Expands Access to Pre-Surgical Monitoring
Market Chameleon (Wed, 20-May 7:31 AM)
